Because tumors bearing a BRAF V600E mutation are oncogenically addicted to this hyperactivated signaling cascade, it was postulated, and later confirmed, that small-molecule inhibitors targeting BRAF V600E offer an effective therapeutic strategy for these cancers [75]. Here, BRAF is linked to cancer.